Focus: CRISPR Therapeutics is a Boston-based biotechnology company pioneering CRISPR-Cas9 gene-editing therapies, primarily focused on ex vivo cell therapy for blood disorders and cancers. The company operates at the forefront of precision gene therapy with a clinically advanced pipeline and strong investor backing.
Profile data last refreshed 5h ago · AI intelligence enriched 8h ago
Stable — net -2 jobs in 30d
4 added, 6 removed. Backfill posture.
CRISPR Therapeutics is an ideal fit for scientists and clinicians seeking exposure to cutting-edge gene therapy at a pivotal clinical inflection point, but with inherent biotech execution and regulatory risk.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for CRISPR Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from CRISPR Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates - tradingview.com
CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates tradingview.com
BlackRock, Inc. Expands CRISPR Therapeutics AG (CRSP) Stake in S - GuruFocus
BlackRock, Inc. Expands CRISPR Therapeutics AG (CRSP) Stake in S GuruFocus
Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy? - The Motley Fool
Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy? The Motley Fool
Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy? - The Globe and Mail
Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy? The Globe and Mail
CRISPR Therapeutics AG $CRSP Shares Sold by Amova Asset Management Americas Inc. - MarketBeat
CRISPR Therapeutics AG $CRSP Shares Sold by Amova Asset Management Americas Inc. MarketBeat
CRISPR Therapeutics AG $CRSP Position Reduced by Sumitomo Mitsui Trust Group Inc. - MarketBeat
CRISPR Therapeutics AG $CRSP Position Reduced by Sumitomo Mitsui Trust Group Inc. MarketBeat
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo